gma semaglutide used for weight loss also helps reduce heart failure symptoms, study finds Demand for weight loss drugs

OM reports grant for advisory board, speakers bureau, through Hadassah University Hospital, medical writing, support for travel, article processing charges from Novo Nordisk, a grant through Hadassah University Hospital from AstraZeneca, speakers bureau from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca, and BOL Pharma, support for travel/meetings from AstraZeneca, and advisory board from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, and BOL Pharma

Numbers come from the SURMOUNT-1 trial and are population averages, not promises for any individual

Do not exceed recommendations for suggested use

Net increases in striatal DA was significantly and positively associated with increases in pituitary R1 ( r (8) = 0.78, p = 0.008, Fig